| To investigate the clinical feature, therapy and prognosis in AIDS patients with Kaposi’s sarcoma. Methods Clinical data of 25 AIDS patients with Kaposi’s sarcoma who were first admitted to Guangzhou Eighth People’s Hospital, Guangzhou Medical University from July 2012 to September 2020 were collected, and their clinical feature, survival and adverse reactions of patients with different chemotherapy regimens were retrospectively analyzed. Results Among 25 AIDS patients with Kaposi’s sarcoma, 15 cases aged＞35 years, 16 cases had CD4+ T lymphocyte count of＜200 cells/ml and 14 cases had HIV RNA of＜100 000 IU/ml. Five patients have undergone antiretroviral therapy prior to the diagnosis. Compared with mono-therapy groups, the ifosfamide+liposomal doxorubicin group achieved complete remission quickly after 4 cycles (P＜0.05), but there was no significant difference in overall survival after the chemotherapy was completed (P＞0.05) and exhibited slightly greater adverse reactions to chemotherapy. Conclusions AIDS patients with Kaposi’s sarcoma usually occurs in middle-aged and young men with poor immunity, and has a higher incidence of opportunistic infections. Integrase inhibitor antiretroviral therapy is preferred. Ifosfamide+liposomal doxorubicin may obtain complete remission earlier than the mono-therapy, but the incidence of adverse reactions (bone marrow suppression and alopecia) is higher. Therefore, treatment regimen can be selected according to the general condition, the speed of disease progression and the requirements of patients. |